Cryptensive

    Biotech companies

    Reviews of the biotech and pharma companies that matter: what they make, whether it is new, who they compete with, and what could move the stock next.

    CompanyPrice1 day1 yearMarket capLast yearAreaWhat they make
    Eli LillyLLY
    		$1,354.00▼ 0.79%▲ 46.48%$1.21TObesity & diabetesThe obesity and diabetes leader (Mounjaro, Zepbound, Foundayo pill), now the world's most valuable drugmaker.
    Novo NordiskNVO
    		$40.31▲ 0.02%▼ 11.76%$177.81BObesity & diabetesThe inventor of Ozempic and Wegovy, now fighting falling prices, generics and Eli Lilly.
    Vertex PharmaceuticalsVRTX
    		$547.09▲ 0.85%▲ 33.61%$138.58BRare diseasesNear-monopoly in cystic fibrosis, plus the first CRISPR therapy and a new non-opioid painkiller.
    GSKGSK
    		$50.33▼ 0.16%▲ 7.93%$102.17BVaccines & mRNALarge British drugmaker in vaccines, HIV and cancer, which bought Nuvalent for its lung cancer pills.
    ModernaMRNA
    		$254.19▲ 5.27%▲ 935.82%$101.47BVaccines & mRNAThe mRNA vaccine pioneer, now betting on a personalized cancer vaccine with Merck.
    Revolution MedicinesRVMD
    		$192.28▲ 8.24%▲ 215.16%$41.21BCancerMaker of Rasonque, the first drug aimed broadly at RAS, the gene behind most pancreatic cancers.
    ExelixisEXEL
    		$69.57▲ 1.25%▲ 70.47%$16.98BCancerProfitable cancer company built on Cabometyx, now trying to line up its successor, zanzalintinib.
    Corcept TherapeuticsCORT
    		$72.77▲ 1.59%▼ 1.29%$7.87BCancerProfitable cortisol specialist whose new ovarian cancer drug took off after an FDA rejection in Cushing's syndrome.
    Praxis Precision MedicinesPRAX
    		$277.62▲ 5.72%▲ 65.03%$7.75BBrain & painBrain disease company with two FDA decisions due within five weeks, for epilepsy and essential tremor.
    CRISPR TherapeuticsCRSP
    		$50.07▲ 3.11%▼ 9.16%$4.83BGene editingCo-owner of Casgevy, the first CRISPR medicine, now testing one-time gene edits for heart disease.
    Viridian TherapeuticsVRDN
    		$28.49▼ 0.21%▲ 3.83%$3.23BImmunologyNew rival to Amgen's Tepezza in thyroid eye disease, with its first drug approved in June 2026.
    Agios PharmaceuticalsAGIO
    		$29.41▲ 4.03%▼ 27.69%$1.76BRare diseasesMaker of mitapivat, a pill for rare blood disorders, waiting for an FDA decision in sickle cell disease.
    SavaraSVRA
    		$4.83▲ 10.27%▲ 22.28%$992.56MRare diseasesSingle-drug company with an inhaled medicine for a rare lung disease that has no approved treatment.
    Capricor TherapeuticsCAPR
    		$9.00▲ 4.65%▲ 51.77%$522.9MRare diseasesSmall company whose cell therapy for Duchenne muscular dystrophy faces an FDA decision on 22 November 2026.
    Unicycive TherapeuticsUNCY
    		$3.55▲ 2.01%▼ 23.16%$99.05MHeart & kidneyTiny kidney drug company whose phosphate pill has been rejected twice over an outside factory.

    Share prices by Yahoo Finance, as of Nov 9, 03:37 AM ET. Not financial advice.

    How we review a biotech company

    • What they make. Each medicine, what it treats, and whether it is truly new (first-in-class), better than what exists (best-in-class) or a follower.
    • The pipeline. Every drug still in trials and how far it has got, from early lab work to an FDA filing.
    • Upcoming dates. Trial results, FDA decisions and earnings: the days that can move a biotech stock 20% or more.
    • The competition. Who else sells or develops a medicine for the same disease.
    • Money and patents. Sales, cash and how long it lasts, and when the main patents run out.
    • The stock. A live price chart for listed companies; for private ones, any IPO plans, the parent company or the main investors.

    Latest biotech news